The Institute for Clinical and Economic Review, a small nonprofit in Boston, developed a new value assessment framework to measure the value of drugs.
Here are five things to know.
1. The framework breaks down the value of drugs into two main concepts: long-term value for money and short-term affordability.
2. Aspects of long-term value include comparative clinical effectiveness, incremental cost-effectiveness, contextual considerations and other benefits or disadvantages. Short-term affordability focuses on potential budget impact, according to the report.
3. More than 50 organizations submitted more than 300 pages of comments and suggestions for the framework during a national public comment period in late 2016, according to the report.
4. ICER hopes the framework will help inform decisions aimed at achieving sustainable access to high value care for all patients, according to the report.
5. The nonprofit is taking on an influential role in the drug industry — payers already cite ICER's work when negotiating prices with drug companies, reports STAT.
More articles on supply chain:
Shifting drug production back to US could raise prices: 5 takeaways
5 ways to prepare your supply chain for a disaster
Mayo Clinic physician: A stripped down FDA would be 'chaotic'